HFE2 Antibody | 64-069

HFE2 Antibody | 64-069 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: Predicted species reactivity based on immunogen sequence: Mouse, Rat

Immunogen: This HFE2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 308-338 amino acids from the C-terminal region of human HFE2.

Research Area: Cell Cycle, Obesity, Neuroscience, Signal Transduction

Tested Application: WB, Flow

Application: For WB starting dilution is: 1:1000
For FACS starting dilution is: 1:10~50

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: 45 kDa

Validation: N/A

Isoform: N/A

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Clonality: Polyclonal

Clone: N/A

Isotype: Rabbit Ig

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.

Concentration: batch dependent

Storage Condition: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: Hemojuvelin, Hemochromatosis type 2 protein, RGM domain family member C, HFE2, HJV, RGMC

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: HFE2 is involved in iron metabolism. It may be a component of the signaling pathway which activates hepcidin or it may act as a modulator of hepcidin expression. It could also represent the cellular receptor for hepcidin. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene. Defects in this gene are the cause of hemochromatosis type 2A, also called juvenile hemochromatosis (JH) . JH is an early-onset autosomal recessive disorder due to severe iron overload resulting in hypogonadotrophic hypogonadism, hepatic fibrosis or cirrhosis and cardiomyopathy, occurring typically before age of 30.